OptiBiotix Health launches new and improved CholBiome®X3 dosage form
A global leader in microbiome modulation technology for use in functional foods and supplements, OptiBiotix Health PLC (‘OptiBiotix’) has announced the launch of a new version of CholBiome®X3.
The innovative new version of CholBiomeX3 is approximately 50% smaller than the original tri-layer tablet, making it easier for individuals to consume. The cholesterol-reducing food supplement combines the same scientifically backed, natural and active ingredients to deliver identical health benefits as its innovative predecessor.
Steven Riley, Director of Marketing and Consumer Sales at OptiBiotix, said: “We carry out surveys, regularly ask for feedback and analyse reviews from our direct customers to ensure our products meet their needs and remains suitable for the market. Following feedback on CholBiomex3, our team has developed a tablet that is half the size of the original to enable easier consumption, while retaining its cholesterol-reducing capabilities. We are delighted to announce that this new and improved version of CholBiomeX3 has now launched in the OptiBiotix Online store and is available for consumers to purchase from today.”
The allergen-free, vegan food supplement contains the company’s patented probiotic strain Lactobacillus plantarum LPLDL®, which was originally isolated from tomatoes and discovered from a collection of more than 4,000 microbial candidates. Having demonstrated its efficacy in human clinical studies, LPLDL has been shown to lower total cholesterol by up to 36.7%, reduce the ‘bad’ low-density lipoprotein (LDL) by up to 13.9% and increase the ‘good’ high-density lipoprotein (HDL) by up to 4.5%.
LPLDL works synergistically alongside Monacolin K from red yeast rice and Vitamin B3 (Niacin) to offer a unique, multi-target mechanism of action in CholBiomeX3, thereby reducing cholesterol levels and improving overall cardiovascular health.
“The feedback from CholBiomeX3 users continues to be positive,” added Riley. “Previous surveys conducted have demonstrated that 96% of all respondents considered the tri-layer tablet to be an effective approach to cholesterol reduction, while 92% of those would also recommend it to others to support a healthier lifestyle. We believe that reducing the size of CholBiomeX3 will not only boost positive feedback, but also make it more appetizing for consumers.”
The smaller version of CholBiomeX3 is now available to purchase in the OptiBiotix Online Store. For more information on the CholBiome range, please visit: https://optibiotix.online/collections/cholbiome-range